Hedge Fund and Insider Trading News: Marc Lasry, Michael Platt, Senvest Management, Maverick Capital, Muddy Waters Capital, Tramondo Investment Partners, Biodesix Inc (BDSX), and More

Billionaire Private-Equity Firm Chief Lasry Says He’s Waiting for People to Get Nervous (Market Watch)
Marc Lasry, the co-founder, chairman and chief executive of private-equity firm and hedge-fund investor Avenue Capital, has seen plenty of success in the sports world, as the Milwaukee Bucks he co-owns are the defending National Basketball Association champions, and have the second-best odds to repeat. But while he has reason to be optimistic about hoops, he says he’s more downbeat on financial markets.

Tiger Cubs Are Off to a Rocky Start in 2022 (Institutional Investor)
Maverick, Light Street, and other Tiger descendants reported sharp first-quarter losses. Lee Ainslie III’s Maverick Capital is the latest tech fund and Tiger Cub to report a sharp loss in March and the first quarter. Its long-short Maverick Fund suffered a roughly 13 percent decline in March and was down nearly 23 percent for the quarter, according to a hedge fund database.

A Hedge Fund that Made $700 Million on its GameStop Bet is Now After Unloved Oil and Gas Stocks (Business Insider)
One hedge fund that managed to walk away with a $700 million profit on its GameStop investment is now targeting beaten-down oil and gas stocks and says sustainability-focussed investors are missing the opportunity here. New York-based hedge fund Senvest Management bet on GameStop even before the Reddit-fueled mania sent its stock soaring, and pocketed one of the great fortunes from the market frenzy.

Pressmaster/Shutterstock.com

Billionaire Platt-Backed Engitix Inks Takeda Partnership (Bloomberg)
U.K.-based biotech firm Engitix Ltd. and Japanese drugmaker Takeda Pharmaceutical Co. have agreed to extend their existing partnership in a deal could be valued at as much as $300 million. Engitix, whose backers include billionaire hedge fund manager Michael Platt, will work with Takeda to jointly develop novel therapeutics for fibrostenotic inflammatory bowel disease, or IBD, including Crohn’s disease and ulcerative colitis, according to a statement seen by Bloomberg News.

Tramondo Launches European Equity Strategy (Hedge Week)
Tramondo Investment Partners (Tramondo), a bank-independent Zug, Switzerland-based investment boutique, has launched Dynamic Equity Europe, a sub-fund of Tramondo UCITS Funds. The strategy of the Dynamic Equity Europe Fund is a carve-out of the firm’s global defensive equity strategy with active risk management, which has been trading since 2017. Focusing on Europe ex Switzerland, Dynamic Equity Europe pursues the same conservative equity approach that participates in equity markets while looking to preserve capital in turbulent times.